Literature DB >> 24097013

Quantitation of metformin in human plasma and urine by hydrophilic interaction liquid chromatography and application to a pharmacokinetic study.

Flemming Nielsen1, Mette M H Christensen, Kim Brøsen.   

Abstract

We describe an analytical method for the quantification of the widely used antihyperglycemic agent, metformin, in human plasma and urine. The separation was performed using isocratic hydrophilic interaction liquid chromatography on a Luna hydrophilic interaction liquid chromatography column (125 × 4.6 mm, 3 μm). The sample preparation was accomplished by solid-phase extraction. Validation of the method was performed in the range 10-2000 ng/mL for plasma and 5-30 mcg/mL for urine. The methods were linear within the investigated range (r(2) > 0.988). Within-day repeatability ranged from 3.1% to 7.5% in plasma and 1.6% to 6.2% in urine. Between-day reproducibility ranged from 2.9% to 5.3% in plasma and 0.6% to 1.8% in urine. The inaccuracy expressed as bias ranged from -3.1% to 1.9% in plasma and from -7.2% to 0.7% in urine. The lower limit of quantification for metformin in plasma was 5 ng/mL and in urine was 40 ng/mL. The method was therefore considered to be precise, accurate, reproducible, and sensitive enough to be appropriate for pharmacokinetic studies of metformin. The applicability of the method for human pharmacokinetic studies was demonstrated by dosing a healthy male volunteer with 500-mg metformin hydrochloride as a single oral dose; plasma and urine concentrations were measured for 24 hours.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24097013     DOI: 10.1097/FTD.0b013e3182a4598a

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  5 in total

1.  Steady-state pharmacokinetics of metformin is independent of the OCT1 genotype in healthy volunteers.

Authors:  Mette Marie Hougaard Christensen; Kurt Højlund; Ole Hother-Nielsen; Tore Bjerregaard Stage; Per Damkier; Henning Beck-Nielsen; Kim Brøsen
Journal:  Eur J Clin Pharmacol       Date:  2015-05-05       Impact factor: 2.953

2.  Intake of St John's wort improves the glucose tolerance in healthy subjects who ingest metformin compared with metformin alone.

Authors:  Tore Bjerregaard Stage; Rasmus Steen Pedersen; Per Damkier; Mette Marie Hougaard Christensen; Søren Feddersen; John Teilmann Larsen; Kurt Højlund; Kim Brøsen
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

3.  Design of a cluster-randomized trial of the effectiveness and cost-effectiveness of metformin on prevention of type 2 diabetes among prediabetic Mexican adults (the PRuDENTE initiative of Mexico City).

Authors:  Luis A Rodríguez; Simón Barquera; Carlos A Aguilar-Salinas; Jaime Sepúlveda-Amor; Luz María Sánchez-Romero; Edgar Denova-Gutiérrez; Nydia Balderas; Lizbeth Moreno-Loaeza; Margaret A Handley; Sanjay Basu; Oliva López-Arellano; Alberto Gallardo-Hernández; Dean Schillinger
Journal:  Contemp Clin Trials       Date:  2020-06-21       Impact factor: 2.226

4.  PRE-surgical Metformin In Uterine Malignancy (PREMIUM): a Multi-Center, Randomized Double-Blind, Placebo-Controlled Phase III Trial.

Authors:  Sarah J Kitson; Zoe Maskell; Vanitha N Sivalingam; Jennifer L Allen; Saad Ali; Sean Burns; Kyle Gilmour; Rahamatulla Latheef; Richard J Slade; Philip W Pemberton; Joseph Shaw; W David Ryder; Henry C Kitchener; Emma J Crosbie
Journal:  Clin Cancer Res       Date:  2018-12-18       Impact factor: 12.531

5.  Hydrophilic Interaction Liquid Chromatography-Electrospray Ionization Mass Spectrometry for Therapeutic Drug Monitoring of Metformin and Rosuvastatin in Human Plasma.

Authors:  Nikolaos Antonopoulos; Giorgos Machairas; George Migias; Ariadni Vonaparti; Vasiliki Brakoulia; Constantinos Pistos; Dimitra Gennimata; Irene Panderi
Journal:  Molecules       Date:  2018-06-27       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.